These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7103624)

  • 1. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.
    Kyle RA; Wagoner RD; Holley KE
    Arch Intern Med; 1982 Aug; 142(8):1445-7. PubMed ID: 7103624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of primary amyloidosis with melphalan and prednisone.
    Schwartz RS; Cohen JR; Schrier SL
    Arch Intern Med; 1979 Oct; 139(10):1144-7. PubMed ID: 485747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.
    Cohen HJ; Lessin LS; Hallal J; Burkholder P
    Ann Intern Med; 1975 Apr; 82(4):466-73. PubMed ID: 1119764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
    Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
    Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AL amyloidosis: therapeutic response in two patients with renal involvement.
    Goddard IR; Jackson R; Jones JM
    Nephrol Dial Transplant; 1991; 6(8):592-4. PubMed ID: 1956560
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.
    Kyle RA; Greipp PR
    Blood; 1978 Oct; 52(4):818-27. PubMed ID: 356916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
    Benson MD
    Arthritis Rheum; 1986 May; 29(5):683-7. PubMed ID: 3718560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival.
    Christou L; Hatzimichael EC; Sotsiou-Candila F; Siamopoulos K; Bourantas KL
    Acta Haematol; 1999; 101(4):202-5. PubMed ID: 10436302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
    Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
    Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary amyloidosis associated to severe factor X deficiency].
    Pérez Martínez J; Llamas F; López Montes A; Massó P; Poblet E; López Rubio E; Gallego E; Gómez Roldán C
    Nefrologia; 2004; 24(5):493-8. PubMed ID: 15648909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
    Quitt M; Aghai E; David M; Kohan R; Ben Ari Y; Froom P
    Scand J Haematol; 1985 Aug; 35(2):155-7. PubMed ID: 3876596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of primary amyloidosis by melphalan and prednisolone: a case report.
    Nakayama M; Kashiwagi M; Katafuchi R; Hori K; Hayashi S; Fujimi S
    Clin Nephrol; 2005 Mar; 63(3):215-20. PubMed ID: 15786823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary amyloidosis with nephrotic syndrome: 5 year follow-up under polychemotherapy. A case report (author's transl)].
    Emmerich B; Kircher A; Fink U; Schmid L; Rastetter J
    Klin Wochenschr; 1980 Nov; 58(21):1207-13. PubMed ID: 7453105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response rates and survival in primary systemic amyloidosis.
    Gertz MA; Kyle RA; Greipp PR
    Blood; 1991 Jan; 77(2):257-62. PubMed ID: 1985692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The successful treatment of primary amyloidosis with intermittent chemotherapy.
    Bradstock K; Clancy R; Uther J; Basten A; Richards J
    Aust N Z J Med; 1978 Apr; 8(2):176-9. PubMed ID: 277166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
    Kyle RA; Gertz MA; Greipp PR; Witzig TE; Lust JA; Lacy MQ; Therneau TM
    N Engl J Med; 1997 Apr; 336(17):1202-7. PubMed ID: 9110907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotic syndrome secondary to amyloidosis.
    Kneipp S; Himmelstein SB
    Nurse Pract; 2000 Jun; 25(6 Pt 1):78, 81, 85-6 passim. PubMed ID: 10884998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-survival case of systemic AL amyloidosis with nephrotic syndrome.
    Katagiri T; Miyazawa K; Yahata N; Gotoh A; Serizawa H; Ohyashiki K
    Intern Med; 2002 Nov; 41(11):1052-5. PubMed ID: 12487190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.